459 related articles for article (PubMed ID: 28635319)
1. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
7. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
8. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
10. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.
Vandiver A; Girardi N; Alhariri J; Garza LA
Int J Dermatol; 2017 Aug; 56(8):833-835. PubMed ID: 28322434
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
Olsen EA; Kornacki D; Sun K; Hordinsky MK
J Am Acad Dermatol; 2020 Feb; 82(2):412-419. PubMed ID: 31622643
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
13. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
14. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
15. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient.
Ramot Y; Zlotogorski A
Skin Appendage Disord; 2018 Apr; 4(2):122-124. PubMed ID: 29765973
[TBL] [Abstract][Full Text] [Related]
16. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
17. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
18. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
19. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]